Premium
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
Author(s) -
Lopes Alves Isadora,
Collij Lyduine E.,
Altomare Daniele,
Frisoni Giovanni B.,
SaintAubert Laure,
Payoux Pierre,
Kivipelto Miia,
Jessen Frank,
Drzezga Alexander,
Leeuwis Annebet,
Wink Alle Meije,
Visser Pieter Jelle,
Berckel Bart N.M.,
Scheltens Philip,
Gray Katherine R.,
Wolz Robin,
Stephens Andrew,
Gismondi Rossella,
Buckely Christopher,
Gispert Juan Domingo,
Schmidt Mark,
Ford Lisa,
Ritchie Craig,
Farrar Gill,
Barkhof Frederik,
Molinuevo José Luis
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12069
Subject(s) - positron emission tomography , amyloid (mycology) , medicine , disease , natural history , prospective cohort study , cohort , β amyloid , neuroimaging , alzheimer's disease , oncology , pathology , psychology , nuclear medicine , psychiatry
The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer's disease (AD). AMYPAD PNHS adds (semi‐)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD‐related progression as well as address methodological challenges in amyloid PET. Methods AMYPAD PNHS is an open‐label, prospective, multi‐center, cohort study recruiting from multiple PCs. Around 2000 participants will undergo baseline amyloid positron emission tomography (PET), half of whom will be invited for a follow‐up PET 12 at least 12 months later. Results Primary include several amyloid PET measurements (Centiloid, SUVr, BP ND , R 1 ), and secondary are their changes from baseline, relationship to other amyloid markers (cerebrospinal fluid and visual assessment), and predictive value of AD‐related decline. Expected Impact Determining the role of amyloid PET for the understanding of this complex disease and potentially improving secondary prevention trials.